# Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

> **NCT01459380** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Cystadenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Undifferentiated Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01459380
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-11
- **Primary completion:** 2016-06-08
- **Final completion:** 2017-02-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01459380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01459380, "Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01459380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*